Europe NGS Market by Offering (Kits [Library Prep, QC, DNA Extraction], System), Type (Genome, Exome, Targeted), Application (Reproductive, Oncology, Infectious, CVD, Drug Discovery), Technology (SBS, Nanopore, Nanoball, SMRT Seq, DNB) – Forecast to 2030

The Europe NGS Market is expected to grow at a CAGR of 14.8% from 2024 to 2030 to reach $6.40 billion by 2030. The field of genomics has surpassed expectations over the past three decades due to massive changes in technology that allowed researchers to interrogate larger pieces of the human genome. Next-generation Sequencing (NGS) is one such massively parallel or deep sequencing technology that helps identify the sequence of nucleotides in DNA/RNA. Due to its high-throughput production, efficient instrument run, and lower cost compared to the traditional Sanger first-generation sequencing method, NGS is highly preferred for large-scale genomic and transcriptomic sequencing.

The growth of this market is driven by factors such as the rising cancer prevalence and increasing application of NGS in cancer treatment and research, the declining costs of genome sequencing, technological advancements in sequencing, and increasing pharmaceutical R&D expenditures. However, the high costs of NGS systems and consumables and the availability of alternative technologies restrain the market's growth.

Additionally, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, and government initiatives supporting large-scale genomic sequencing projects are expected to offer significant market growth opportunities. However, the lack of skilled professionals and regulatory and standardization concerns in diagnostic testing pose a significant challenge to the market's growth.

Rising Cancer Prevalence and Increasing Application of NGS in Cancer Treatment and Research Driving the Market's Growth

The prevalence of cancer is rising across the world. According to GLOBOCAN, in 2020, 4.4 million people were diagnosed with cancer in Europe. This number is expected to rise to 4.9 million by 2030. The most common types of cancer are lung cancer, breast cancer, colon cancer, prostate cancer, and rectum cancer. The utilization of NGS is growing in cancer treatment and research. NGS has been proven as an effective method for gaining a more precise and comprehensive understanding of the molecular foundations of individual cancers.

Targeted medicines are quickly becoming the new standard of care for cancer. Also, NGS is currently starting to be used in clinical oncology to improve cancer therapy through a variety of techniques, including the discovery of novel and rare cancer mutations, the identification of cancer mutation carriers, and the development of specialized therapeutic approaches known as personalized medicine (PM). Further, NGS has the additional advantage of offering an expanded view of the disease landscape and revealing cancer development pathways. Thus, the rising cancer prevalence and increasing application of NGS in cancer treatment drive the demand for NGS in Europe.

Click here to: Get Free Sample Pages of this Report

The Increasing Applications of NGS Create an Opportunity for the Market

NGS has gained much significance in clinical practices for oncology, reproductive health, Mendelian disorders, complex diseases, and infectious diseases. In the coming years, NGS is expected to diversify in other clinical areas, with a considerable reduction in sequencing costs. The technology is expected to show substantial penetration in applications such as liquid biopsies for the early detection and monitoring of cancer and reproductive health applications. New biomarkers and actionable mutations are being identified by researchers. For instance, in February 2024, Dxcover Limited (U.K.) raised USD 11.9 million in funding to support the development of a liquid biopsy technology platform for the diagnosis of early-stage cancers, which includes colorectal and brain cancers. NGS-based liquid biopsy analysis finds a small quantity of remaining tumor DNA or RNA in post-treatment samples, which enables responses to treatment monitoring and early disease detection, creating growth opportunities for the players operating in the NGS market.

Key Findings in the Europe NGS Market Study:

Consumables Segment to Account for the Largest Share of the Market in 2024

Among the offerings, in 2024, the consumables segment is expected to account for the largest share of the Europe NGS market. The recurring use of consumables and advancements in target enrichment protocols and associated consumables. Many companies are focusing on partnerships to enhance their consumable offerings. For instance, in February 2022, QIAGEN N.V. (Netherlands) partnered with Element Biosciences, Inc. (U.S.) to validate a selection of its NGS library prep and target enrichment offerings on the latter’s AVITI System.

Targeted Genome Sequencing Segment to Account for the Largest Share of the Market in 2024

Among sequencing types, in 2024, the targeted genome sequencing segment is expected to account for the largest share of the Europe NGS market. The large share of this segment is attributed to low sequencing costs as compared to other sequencing technologies, higher sensitivity of the technique to call variants, and advancements in targeted genome sequencing technologies. Advancements in targeted genome sequencing have improved the diagnosis of monogenic intestinal and pediatric disorders. In addition to disease diagnosis, this technology has enabled researchers to study gene-drug associations, which has helped researchers design gene-specific drugs with high specificity.

Sequencing by Synthesis Segment to Account for the Largest Share of the Market in 2024

Among the technologies, in 2024, the sequencing by synthesis segment is expected to account for the largest share of the Europe NGS market. The key factors supporting the large market share of this segment are low sequencing costs compared to other sequencing technologies such as ion semiconductor sequencing, nanopore sequencing, and many others, higher sensitivity of the technique to call variants, and proven results in identifying primary immunodeficiencies and specific gene-associated diseases.

Research and Other Applications Segment to Account for the Largest Share of the Market in 2024

Among the applications, in 2024, the research and other applications segment is expected to account for the largest share of the Europe NGS market. The increasing adoption of sequencing-based tests in laboratories, the growing demand for personalized medicines, the increasing NGS-based research, and the growing prevalence of genetic disorders. For instance, according to the data published by the German Center for Lung Research in July 2024, in Germany, approximately 2,500 newborns were affected with cystic fibrosis in 2022.

Pharmaceutical & Biotechnology Companies Segment to Account for the Largest Share of the Europe NGS Market in 2024

Among the end users, in 2024, the pharmaceutical & biotechnology segment is expected to account for the largest share of the Europe NGS market. The large market share of this segment is attributed to factors such as the increasing adoption of advanced technologies for research purposes and increasing research for drug discovery with widening NGS applications, rising incidence of chronic diseases, and increasing R&D spending by pharmaceutical & biotechnology companies. For instance, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) data, in 2020, global pharmaceutical R&D spending was USD 189 billion, which is expected to increase up to USD 202 million by 2024. NGS enables pharmaceutical & biotechnology companies to identify and validate biomarkers that can be used in developing new diagnostic tests and therapies, which drives the adoption of NGS among pharmaceutical & biotechnology companies.

Germany to Account for the Largest Market Share in 2024

In 2024, Germany is expected to account for the largest share of the Europe NGS market. The large share is primarily attributed to the increasing number of sequencing projects, growing research for the development of personalized medicine in the country, the establishment of new healthcare facilities and modernizing existing ones, the large pool of patients with gene-associated disorders, growing research activities for developing personalized medicines, and the rising prevalence of cancer. For instance, according to GLOBOCAN, 19.3 million people were diagnosed with cancer in 2020. This number is expected to rise to 24.6 million by 2030. NGS has helped to make it easy for researchers to identify and clarify hundreds of genes linked to cancer; these discoveries are certain to contribute to the identification of new therapeutic targets.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past three years 2020–2024. The key players profiled in the Europe NGS market report are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), and 10X Genomics, Inc. (U.S.).

Scope of the Report:

Europe NGS Market Assessment, by Offering

• Consumables
  • Sample Preparation Consumables
    • DNA Extraction and Amplification
    • Library Preparation & Target Enrichment
    • Quality Control
  • Other Consumables
• NGS Platforms/Instruments
• Software
• Services
  (Note: Other consumables include vials, pipettes, containers, trays, sequencing reagents, flow cells, and tubes.)

Europe NGS Market Assessment, by Sequencing Type

• Targeted Genome Sequencing
• Whole Genome Sequencing
• Whole Exome Sequencing
• Other Sequencing Types
  (Note: Other sequencing types include degradome sequencing, chromatin immunoprecipitation (ChIP) sequencing, and methylation sequencing.)

Europe NGS Market Assessment, by Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single-molecule Real-time Sequencing (SMRT)
• Nanopore Sequencing
• DNA nanoball sequencing

Europe NGS Market Assessment, by Application

• Research Applications
  • Drug Discovery
  • Agriculture & Animal Research
  • Other Research Applications
• Clinical Applications
  • Reproductive Health Diagnosis
  • Oncology
  • Infectious Diseases
  • Other Clinical Applications
    (Note: Other research applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies, and other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.)

Europe NGS Market Assessment, by End User

• Hospitals and Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Academic Institutes & Research Centers
• Other End Users
  (Note: Other end users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.)

Europe NGS Market Assessment, by Geography

• Germany
• France
• U.K.
• Italy
• Spain
• Switzerland
• Rest of Europe

Key questions answered in the report: